| |
Tuesday, April 4, 2023 | 10am ET / 7am PT Life sciences leaders are reporting that investments in cloud technology are opening new doors for enhanced productivity, improved time-to-insights, and more. Join this one-hour deep dive into the latest solutions and strategies for successfully accelerating innovation while optimizing costs. Register now. .png)
|
|
Today's Big NewsApr 21, 2023 |
|
May 1 - 3, 2023 | Jersey City, NJ Examine how the current changes to field medical will affect the role moving forward. Only a few weeks left, Register Today! .png)
|
|
| By Nick Paul Taylor Daiichi Sankyo’s long wait for approval of quizartinib just grew a little longer. Having bounced back from a 2019 rejection, the Japanese drugmaker has now learned the FDA needs another three months to review its second attempt to launch a challenger to Astellas and Novartis in a blood cancer market. |
|
|
|
By Nick Paul Taylor Boehringer Ingelheim has tapped RetinAI to support its attempt to develop treatments for geographic atrophy, striking a deal to apply AI tools to its imaging data in a search for novel biomarkers and predictors of disease progression. |
By Helen Floersh Jennifer Doudna's Innovative Genomics Institute will use a new $70 million grant from TED to develop gene editing and metagenomics tools to reduce greenhouse gases from cow burps. |
Sponsored by YPrime Michael Hughes, Chief Product Officer at YPrime discusses the benefits and challenges of eConsent implementation and how to circumvent the biggest barriers to adoption. |
By Max Bayer,Gabrielle Masson President Joe Biden will tap the current head of the National Cancer Institute and former cancer surgeon Monica Bertagnolli, M.D., to lead the National Institutes of Health. The move is the first permanent replacement for the federal institute after Francis Collins retired in 2021. |
By Joseph Keenan Taros Chemicals, a German small molecule CRO, inked a partnership deal with Spain’s Welab in an effort to broaden their scope of R&D offerings to clients. |
By Conor Hale The biotech has signed on with Big Blue to explore the use of quantum computers in developing its future medicines, using systems that could make it easier to solve the tricky molecular-modeling problems that have, at times, been too complex for previous generations of hardware. |
By Fraiser Kansteiner In February, a federal judge said Merck & Co. and Glenmark Pharmaceuticals would have to face a jury trial over an alleged pay-for-delay deal tied to the cholesterol med Zetia. Now, two plaintiff groups have gotten in line behind settlement offers. But holdouts could still force Merck and Glenmark to defend themselves in court. |
By Kevin Dunleavy Applying lessons learned from its first failed bankruptcy for talc lawsuits may produce dividends for Johnson & Johnson. Thursday, U.S. bankruptcy judge Michael Kaplan froze more than 38,000 lawsuits for 60 days as part of the company’s second attempt to declare bankruptcy for its subsidiary, LTL Management, which was established to hold the cases |
By Teresa Carey This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
By Angus Liu J&J and Legend Biotech's Carvykti showed a massive cancer progression benefit in leaked multiple myeloma trial data. The pair also enlisted Novartis to help ramp up supply. Meanwhile, Novartis and BeiGene's tislelizumab came back with a broader win in stomach cancer. Plus more. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
